Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
AstraZeneca (NASDAQ: AZN) has unveiled plans to invest $50 billion in U.S. manufacturing and R&D infrastructure by 2030, marking one of the largest expansions in the pharmaceutical industry. The move responds to renewed pressure from President Donald Trump’s administration to localize drug production and reduce reliance on imports.
The Anglo-Swedish drugmaker will build a new manufacturing plant in Virginia focused on active ingredients for weight-loss drugs, including a GLP-1 candidate and an oral PCSK9 inhibitor. It also plans to expand operations in Maryland, Massachusetts, California, Indiana, and Texas, enhancing its R&D capabilities and clinical trial supply chain.
CEO Pascal Soriot announced the investment in Washington, citing the need for global pricing reform. “The U.S. cannot shoulder the world’s R&D costs alone,” he said, calling for other nations to pay more for drugs.
Over 40% of AstraZeneca’s 2024 revenue came from the U.S., the world’s largest pharmaceutical market valued at $635 billion. The company aims to hit $80 billion in annual revenue by 2030, with half coming from the U.S.
The $50 billion pledge follows Trump’s threats of pharmaceutical tariffs, with a possible grace period of 12–18 months. U.S. Commerce Secretary Howard Lutnick emphasized the administration’s goal to end foreign dependency in the drug supply chain.
The investment is in addition to a $3.5 billion commitment made in November 2024. It mirrors a similar $50 billion pledge by Roche and aligns with major expansion plans from Eli Lilly, Johnson & Johnson, Novartis, and Sanofi.
AstraZeneca employs about 18,000 people in the U.S. and hinted at creating tens of thousands of new jobs, though exact figures were not disclosed. The company declined to comment on rumors of a potential U.S. stock market listing shift.
